1-5 of 5
Nina Benachour
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: Phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma

Free
Binod Dhakal, Shinsuke Iida, M Hasib Sidiqi, Elena Zamagni, Sung-Soo Yoon, Natalie Callander, Cyrille Touzeau, Quanlin Li, Agnes Balogh, Ana Slaughter, Nina Benachour, Carolina Lonardi, Arnab Ghosh, Martin Vogel, Nikoletta Lendvai, Tamar Lengil, Mythili Koneru, Nitin Patel, Octavio Costa, Vrinda Mahajan, Joaquin Martinez-Lopez, Kwee Yong, Katja Weisel, Xavier Leleu
Journal: Blood
Blood (2025) 146 (Supplement 1): 2215.
https://doi.org/10.1182/blood-2025-2215
Published: 2025
Journal Articles

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

Free
Luciano Costa, Albert Oriol, Dominik Dytfeld, Salomon Manier, Peter Voorhees, Yi Lin, Myo Htut, Wilfried Roeloffzen, Phoebe Joy Ho, Urvi Shah, Man Zhao, Quanlin Li, Agnes Balogh, Katherine Li, Ana Slaughter, Nina Benachour, Carolina Lonardi, Arnab Ghosh, Huabin Sun, Nikoletta Lendvai, Tamar Lengil, Nitin Patel, Mythili Koneru, Erika Florendo, Octavio Costa, Vrinda Mahajan, Paula Rodriguez-Otero, Christopher Strouse, Keith Stewart, Surbhi Sidana
Journal: Blood
Blood (2025) 146 (Supplement 1): 94.
https://doi.org/10.1182/blood-2025-94
Published: 2025
Journal Articles

Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial

Free
Noffar Bar, Roberto Mina, Anne K. Mylin, Hisayuki Yokoyama, Hila Magen, Winfried Alsdorf, Monique C. Minnema, Leyla O. Shune, Iris Isufi, Simon J Harrison, Urvi A. Shah, André De Champlain, Katharine S. Gries, Diana Chen, Quanlin Li, Tzu-Min Yeh, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, William Deraedt, Martin Vogel, Nikoletta Lendvai, Nitin Patel, Octavio Costa Filho, Erika Florendo, Lionel Karlin, Katja C. Weisel
Journal: Blood
Blood (2024) 144 (Supplement 1): 2002.
https://doi.org/10.1182/blood-2024-209232
Published: 2024
Journal Articles

Comparative Efficacy of Ciltacabtagene Autoleucel Versus Isatuximab, Carfilzomib and Dexamethasone in the Treatment of Patients with Lenalidomide-Refractory Multiple Myeloma with 1-3 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Free
Roberto Mina, Paolo Corradini, Michele Cavo, Jesús F. San-Miguel, Leyla O. Shune, Abdullah Mohammad Khan, Surbhi Sidana, Xavier Leleu, Salomon Manier, Brea Lipe, Katja C. Weisel, Suzy van Sanden, Joris Diels, João Mendes, Seina Lee, Sandra Van Hoorenbeeck, Adrián Pons, Ana Slaughter, Nina Benachour, Carolina Lonardi, Arnab Ghosh, Nitin Patel, Erika Florendo, Joaquín Martínez-Lopez
Journal: Blood
Blood (2024) 144 (Supplement 1): 7088.
https://doi.org/10.1182/blood-2024-205189
Published: 2024
Journal Articles

Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial

Free
Rakesh Popat, Albert Oriol, Michele Cavo, Lionel Karlin, Irit Avivi Mazza, Wilfried Roeloffzen, Seok Jin Kim, Brea Lipe, Noffar Bar, Noemi Horvath, Andrew Spencer, Chang-Ki Min, Diana Chen, Quanlin Li, Katherine Li, Ana Slaughter, Carolina Lonardi, Nina Benachour, Arnab Ghosh, Martin Vogel, Nikoletta Lendvai, Tamar Lengil, Nitin Patel, Octavio Costa Filho, Erika Florendo, Yi Lin
Journal: Blood
Blood (2024) 144 (Supplement 1): 1032.
https://doi.org/10.1182/blood-2024-201533
Published: 2024